English
Recombinant Human B7-H4/VTCN1 Protein (aa 29-258, His Tag)
Recombinant Human B7-H4/VTCN1 Protein (aa 29-258, His Tag)
Artikelnummer
ELSPDMH100005-20
Verpackungseinheit
20 µg
Hersteller
Elabscience Biotechnology
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Abbreviation: B7-H4;VTCN1
Target Synonym: B7S1;B7x;Vtcn1;B7h.5;B7-H4;B7H4T-cell costimulatory molecule B7x;B7S1VCTN1;B7XPRO1291;FLJ22418;Immune costimulatory protein B7-H4;Protein B7S1;T cell costimulatory molecule B7x;V-set domain containing T cell activation inhibitor 1;V-set domain-containing T-cell activation inhibitor 1
Target Species: Human
Expression Host: HEK293 Cells
Fusion Tag: C-His
UNIProt ID: Q7Z7D3
Background: V-set domain-containing T-cell activation inhibitor 1; also known as B7X; B7H4; B7S1; and VTCN1; is a single-pass type? membrane protein belonging to the B7 family of costimulatory proteins. These proteins are expressed on the surface of antigen-presenting cells and interact with ligands on T lymphocytes. They provide costimulatory signals that regulate T cell responses. A soluble form of B7H4 has also been detected. B7X / VTCN1 / B7H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation; proliferation; cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages; B7X / VTCN1 / B7H4 plays an important role; together with regulatory T-cells(Treg); in the suppression of tumor-associated antigen-specific T-cell immunity. B7X / VTCN1 / B7H4 is also involved in promoting epithelial cell transformation. This membrane protein can be up-regulated by IL6 / interleukin-6 and IL10 / interleukin-10 and inhibited by CSF2 / GM-CSF and IL4 / interleukin-4 on antigen-presenting cells.
Sequence: Phe29-Ala258
Purity: > 95 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Endotoxin: < 1.0 EU per ug of the protein as determined by the LAL method.
Target Synonym: B7S1;B7x;Vtcn1;B7h.5;B7-H4;B7H4T-cell costimulatory molecule B7x;B7S1VCTN1;B7XPRO1291;FLJ22418;Immune costimulatory protein B7-H4;Protein B7S1;T cell costimulatory molecule B7x;V-set domain containing T cell activation inhibitor 1;V-set domain-containing T-cell activation inhibitor 1
Target Species: Human
Expression Host: HEK293 Cells
Fusion Tag: C-His
UNIProt ID: Q7Z7D3
Background: V-set domain-containing T-cell activation inhibitor 1; also known as B7X; B7H4; B7S1; and VTCN1; is a single-pass type? membrane protein belonging to the B7 family of costimulatory proteins. These proteins are expressed on the surface of antigen-presenting cells and interact with ligands on T lymphocytes. They provide costimulatory signals that regulate T cell responses. A soluble form of B7H4 has also been detected. B7X / VTCN1 / B7H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation; proliferation; cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages; B7X / VTCN1 / B7H4 plays an important role; together with regulatory T-cells(Treg); in the suppression of tumor-associated antigen-specific T-cell immunity. B7X / VTCN1 / B7H4 is also involved in promoting epithelial cell transformation. This membrane protein can be up-regulated by IL6 / interleukin-6 and IL10 / interleukin-10 and inhibited by CSF2 / GM-CSF and IL4 / interleukin-4 on antigen-presenting cells.
Sequence: Phe29-Ala258
Purity: > 95 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Endotoxin: < 1.0 EU per ug of the protein as determined by the LAL method.
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
